Although the latest federal legislature addressing drug serialization and pedigree initially calls for lot-level tracing, a number of companies in the pharmaceutical supply chain have indicated that they will continue with their current efforts toward item-level tracing. As a result, the industry may find itself in a mixed-data environment for some time. This session will focus on how this environment may look, how it might impact your company, the standards that will help companies manage lot- and item-level tracing, and the eventual transition to item-tracing.
Speaker:
Bob Celeste, Pharmaceutical Sector Lead, GS1 US